-
Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a s...
Objective: Breast cancer remains to be the globally leading female cancer. About 15% to 20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive...